Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III Study of Dextromethorphan Hydrobromide and Bupropion Hydrochloride Extended-Release Tablets in Adult Major Depressive Disorder
CTR20250967Phase 3Completed
- Sponsor
- CSPC Ouyi Pharmaceutical
- Start
- Mar 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of dextromethorphan + bupropion in major depressive disorder (MDD), sponsored by CSPC Ouyi Pharmaceutical. Started Mar 2025; status: completed.
02
Drugs
dextromethorphan + bupropion
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on CTR20250967.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20250967.